litlas
Log inCreate account

Joan T. Merrill

Active 1984–2025

163
Papers
34,834
Citations
94
h-index
159
i10-index

Citations

Citations per year for Joan T. Merrill1984: 2 citations1994: 2 citations1998: 1 citations1999: 1 citations2000: 2 citations2001: 5 citations2002: 11 citations2003: 17 citations2004: 18 citations2005: 24 citations2006: 41 citations2007: 43 citations2008: 57 citations2009: 134 citations2010: 157 citations2011: 194 citations2012: 255 citations2013: 299 citations2014: 264 citations2015: 291 citations2016: 393 citations2017: 347 citations2018: 374 citations2019: 1,297 citations2020: 1,265 citations2021: 1,222 citations2022: 1,066 citations2023: 715 citations2024: 1,263 citations2025: 635 citations2026: 6 citations1985–1993: no citations, so these years are not shown1995–1997: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,615 citing papers, 22.9% of this breakdownChina: 926 citing papers, 8.1% of this breakdownUnited Kingdom: 851 citing papers, 7.5% of this breakdownItaly: 601 citing papers, 5.3% of this breakdownGermany: 502 citing papers, 4.4% of this breakdownFrance: 456 citing papers, 4% of this breakdownCanada: 439 citing papers, 3.9% of this breakdownSpain: 391 citing papers, 3.4% of this breakdownSweden: 380 citing papers, 3.3% of this breakdownJapan: 314 citing papers, 2.8% of this breakdownNetherlands: 301 citing papers, 2.6% of this breakdownAustralia: 276 citing papers, 2.4% of this breakdown
0%22.9%Other 29.4%

Institutions

Fields

  • Medicine76.2%
  • Immunology and Microbiology13.6%
  • Biochemistry, Genetics and Molecular Biology8.3%
  • Neuroscience0.5%
  • Computer Science0.2%
  • Health Professions0.2%
  • Other1%

Topics

  • Systemic Lupus Erythematosus Research20.3%
  • T-cell and B-cell Immunology5.9%
  • Rheumatoid Arthritis Research and Therapies4.7%
  • Monoclonal and Polyclonal Antibodies Research3.5%
  • Immune Cell Function and Interaction2.7%
  • Systemic Sclerosis and Related Diseases2.6%
  • Other60.3%

Coauthors

All papers

Open in search
  1. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

    Authors: Michelle Petri, Ana‐Maria Orbai, Graciela S. Alarcón, Caroline Gordon, Joan T. Merrill, Paul R. Fortin, Ian N Bruce, David Isenberg, Daniel J. Wallace, Ola Nived, Gunnar Sturfelt, Rosalind Ramsey‐Goldman, Sang‐Cheol Bae, John G. Hanly, Jorge Sánchez‐Guerrero, Ann E. Clarke, Cynthia Aranow, Susan Manzi, Murray Urowitz, Dafna D. Gladman, Kenneth Kalunian, Melissa Costner, Victoria P. Werth, Asad Zoma, Sasha Bernatsky, Guillermo Ruiz‐Irastorza, Munther A. Khamashta, Søren Jacobsen, Jill P. Buyon, Peter J. Maddison, Mary Anne Dooley, Ronald van Vollenhoven, Ellen M. Ginzler, Thomas Stoll, Christine Peschken, Joseph L. Jorizzo, Jeffrey P. Callen, S. Sam Lim, Barri J. Fessler, Murat İnanç, Diane L. Kamen, Anisur Rahman, Kristján Steinsson, Andrew G. Franks, Lisa Sigler, Suhail Hameed, Hong Fang, Ngoc Minh Pham, Robin L. Brey, Michael H. Weisman, Gerald McGwin, Laurence S. Magder - Arthritis & Rheumatism 2012 cited by 5,295

  2. Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

    Authors: Joan T. Merrill, C. Michael Neuwelt, Daniel J. Wallace, Joseph C. Shanahan, Kevin Latinis, Jim C. Oates, Tammy O. Utset, Caroline Gordon, David Isenberg, Hsin‐Ju Hsieh, David Zhang, Paul Brunetta - Arthritis & Rheumatism 2009 cited by 1,392

  3. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

    Authors: Richard Furie, Michelle Petri, Omid Zamani, Ricard Cervera, Daniel J. Wallace, Dana Tegzová, Jorge Sánchez‐Guerrero, Andreas Schwarting, Joan T. Merrill, Winn Chatham, William Stohl, Ellen M. Ginzler, Douglas R. Hough, Z. John Zhong, William W. Freimuth, Ronald van Vollenhoven, BLISS-76 Study Group - Arthritis & Rheumatism 2011 cited by 1,653

  4. Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus

    Authors: Richard Furie, Munther A. Khamashta, Joan T. Merrill, Victoria P. Werth, Kenneth Kalunian, Philip Z. Brohawn, Gabor G. Illei, Jörn Drappa, Liangwei Wang, Stephen Yoo, for the CD1013 Study Investigators - Arthritis & Rheumatology 2016 cited by 867

  5. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

    Authors: Eric F. Morand, Marilyn C. Pike, Joan T. Merrill, Ronald van Vollenhoven, Victoria P. Werth, Coburn Hobar, Nikolay Delev, Vaishali Shah, Brian J. Sharkey, Thomas Wegman, Ian M. Catlett, Subhashis Banerjee, Shalabh Singhal - Arthritis & Rheumatology 2022 cited by 248

  6. The frequency and outcome of lupus nephritis: results from an international inception cohort study

    Authors: John G. Hanly, Aidan G. O’Keeffe, Li Su, Murray B. Urowitz, Juanita Romero‐Díaz, Caroline Gordon, Sang‐Cheol Bae, Sasha Bernatsky, Ann E. Clarke, Daniel J. Wallace, Joan T. Merrill, David Isenberg, Anisur Rahman, Ellen M. Ginzler, Paul R. Fortin, Dafna D. Gladman, Jorge Sánchez‐Guerrero, Michelle Petri, Ian N Bruce, Mary Anne Dooley, Rosalind Ramsey‐Goldman, Cynthia Aranow, Graciela S. Alarcón, Barri J. Fessler, Kristján Steinsson, Ola Nived, Gunnar Sturfelt, Susan Manzi, Munther A. Khamashta, Ronald van Vollenhoven, Asad Zoma, Manuel Ramos‐Casals, Guillermo Ruiz‐Irastorza, S. Sam Lim, Thomas Stoll, Murat İnanç, Kenneth Kalunian, Diane L. Kamen, Peter J. Maddison, Christine Peschken, Søren Jacobsen, Anca Askanase, Chris Theriault, Kara Thompson, Vernon T. Farewell - Lara D. Veeken 2015 cited by 632

  7. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial

    Authors: Di Wu, Jing Li, Dong Xu, Joan T. Merrill, Ronald van Vollenhoven, Yi Liu, Jiankang Hu, Yang Li, Fen Li, Chenghui Huang, Guochun Wang, Xiaomei Li, Jianhong Zhao, Dongbao Zhao, Cibo Huang, Huaxiang Liu, Wei Wei, Guixiu Shi, Fuai Lu, Xiaoxia Zuo, Liqi Bi, Zhijun Li, Xiaoxia Wang, Miaojia Zhang, Ning Tie, Juan Li, Hanyou Mo, Jianmin Fang, Chunde Bao, Fengchun Zhang - Annals of the Rheumatic Diseases 2023 cited by 140

  8. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

    Authors: Bevra H. Hahn, Maureen McMahon, Alan Wilkinson, William D. Wallace, David Daikh, John FitzGerald, George Karpouzas, Joan T. Merrill, Daniel J. Wallace, Jinoos Yazdany, Rosalind Ramsey‐Goldman, Karandeep Singh, Mazdak A. Khalighi, Soo‐In Choi, Maneesh Gogia, Suzanne Kafaja, Mohammad Kamgar, Christine Lau, W. J. Martin, Sefali Parikh, Justin Peng, Anjay Rastogi, Weiling Chen, Jennifer M. Grossman - Arthritis Care & Research 2012 cited by 1,484

  9. Predictors of Pregnancy Outcomes in Patients With Lupus

    Authors: Jill P. Buyon, Mimi Kim, Marta Guerra, Carl A. Laskin, Michelle Petri, Michael D. Lockshin, Lisa R. Sammaritano, D. Ware Branch, T. Flint Porter, Allen D. Sawitzke, Joan T. Merrill, Mary D. Stephenson, Elisabeth Cohn, Lamya Garabet, Jane E. Salmon - Annals of Internal Medicine 2015 cited by 553

  10. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

    Authors: Munther A. Khamashta, Joan T. Merrill, Victoria P. Werth, Richard Furie, Kenneth Kalunian, Gabor G. Illei, Jörn Drappa, Liangwei Wang, Warren Greth - Annals of the Rheumatic Diseases 2016 cited by 498

  11. Transancestral mapping and genetic load in systemic lupus erythematosus

    Authors: Carl D. Langefeld, Hannah C. Ainsworth, Deborah S. Cunninghame Graham, Jennifer A. Kelly, Mary E. Comeau, Miranda C. Marion, Timothy D. Howard, Paula S. Ramos, Jennifer A. Croker, David Morris, Johanna K. Sandling, Jonas Carlsson Almlöf, Eduardo M. Acevedo‐Vásquez, Graciela S. Alarcón, Alejandra Babini, Vicente Baca, Anders Bengtsson, Guillermo Berbotto, Marc Bijl, Elizabeth E. Brown, Hermine I. Brunner, Mario H. Cardiel, Luís J. Catoggio, Ricard Cervera, Jorge M. Cucho‐Venegas, Solbritt Rantapää‐Dahlqvist, Sandra D’Alfonso, Berta Martins da Silva, Iñigo de la Rúa Figueroa, Andrea Doria, Jeffrey C. Edberg, Emõke Endreffy, Jorge Antonio Esquivel‐Valerio, Paul R. Fortin, Barry I. Freedman, Johan Frostegård, Mercedes García, Ignacio García‐De La Torre, Gary S. Gilkeson, Dafna D. Gladman, Iva Gunnarsson, Joel M. Guthridge, Jennifer L. Huggins, Judith A. James, Cees G. M. Kallenberg, Diane L. Kamen, David R. Karp, Kenneth M. Kaufman, Leah C. Kottyan, László Kovács, Helle Laustrup, Bernard Lauwerys, Quan‐Zhen Li, Marco A. Maradiaga‐Ceceña, Javier Martı́n, Joseph M. McCune, David R. McWilliams, Joan T. Merrill, Pedro C. Miranda, J. F. Moctezuma, Swapan K. Nath, Timothy B. Niewold, Lorena Orozco, Norberto Ortego‐Centeno, Michelle Petri, Christian A. Pineau, Bernardo A. Pons‐Estel, Janet Pope, Prithvi Raj, Rosalind Ramsey‐Goldman, John D. Reveille, Laurie Russell, José Mario Sabio, Carlos A. Aguilar‐Salinas, Hugo R. Scherbarth, R Scorza, Michael F. Seldin, Christopher Sjöwall, Elisabet Svenungsson, Susan D. Thompson, Sergio Toloza, Lennart Truedsson, Teresa Tusié‐Luna, Carlos Vasconcelos, Luis M. Vilá, Daniel J. Wallace, Michael H. Weisman, Joan Wither, Tushar Bhangale, Jorge R. Oksenberg, John D. Rioux, Peter K. Gregersen, Ann‐Christine Syvänen, Lars Rönnblom, Lindsey A. Criswell, Chaim O. Jacob, Kathy L. Sivils, Betty P. Tsao, Laura E. Schanberg, Timothy W. Behrens and 8 more - Nature Communications 2017 cited by 437

  12. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

    Authors: Edward M Vital, Joan T. Merrill, Eric F. Morand, Richard Furie, Ian N Bruce, Yoshiya Tanaka, Susan Manzi, Kenneth Kalunian, Rubana N. Kalyani, Katie Streicher, Gabriel Abreu, Raj Tummala - Annals of the Rheumatic Diseases 2022 cited by 142

  13. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

    Authors: Ian N Bruce, Aidan G. O’Keeffe, Vernon T. Farewell, John G. Hanly, Susan Manzi, Li Su, Dafna D. Gladman, Sang‐Cheol Bae, Jorge Sánchez‐Guerrero, Juanita Romero‐Díaz, Caroline Gordon, Daniel J. Wallace, Ann E. Clarke, Sasha Bernatsky, Ellen M. Ginzler, David Isenberg, Anisur Rahman, Joan T. Merrill, Graciela S. Alarcón, Barri J. Fessler, Paul R. Fortin, Michelle Petri, Kristján Steinsson, Mary Anne Dooley, Munther A. Khamashta, Rosalind Ramsey‐Goldman, Asad Zoma, Gunnar Sturfelt, Ola Nived, Cynthia Aranow, Meggan Mackay, Manuel Ramos‐Casals, Ronald van Vollenhoven, Kenneth Kalunian, Guillermo Ruiz‐Irastorza, Sam Lim, Diane L. Kamen, Christine Peschken, Murat İnanç, Murray B. Urowitz - Annals of the Rheumatic Diseases 2014 cited by 566

  14. The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial

    Authors: Jill P. Buyon, Michelle Petri, Mimi Kim, Kenneth Kalunian, Jennifer Grossman, Bevra H. Hahn, Joan T. Merrill, Lisa R. Sammaritano, Michael D. Lockshin, Graciela S. Alarcón, Susan Manzi, H. Michael Belmont, Anca Askanase, Lisa Sigler, Mary Anne Dooley, Joan Von Feldt, W. Joseph McCune, Alan Friedman, Jane Wachs, Mary E. Cronin, Michelene Hearth-Holmes, M Tan, Frederick Licciardi - Annals of Internal Medicine 2005 cited by 666

  15. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

    Authors: Kenneth Kalunian, Joan T. Merrill, Romeo Maciuca, Jacqueline McBride, Michael J. Townsend, Xiaohui Wei, John C. Davis, William P. Kennedy - Annals of the Rheumatic Diseases 2015 cited by 339

  16. Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes

    Authors: May Y. Choi, Irene A. Chen, Ann E. Clarke, Marvin J. Fritzler, Katherine A Buhler, Murray B. Urowitz, John G. Hanly, Yvan St‐Pierre, Caroline Gordon, Sang‐Cheol Bae, Juanita Romero‐Díaz, Jorge Sánchez‐Guerrero, Sasha Bernatsky, Daniel J. Wallace, David Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey‐Goldman, Susan Manzi, Andreas Jönsen, Graciela S. Alarcón, Ronald van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz‐Irastorza, Sam Lim, Murat İnanç, Kenneth Kalunian, Søren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Jill P. Buyon, David Sontag, Karen H. Costenbader - Annals of the Rheumatic Diseases 2023 cited by 81

  17. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus

    Authors: Joan T. Merrill, Daniel J. Wallace, Stephen Wax, Amy Kao, Patricia A. Fraser, Peter Chang, David Isenberg, on behalf of the ADDRESS II Investigators - Arthritis & Rheumatology 2017 cited by 241

  18. Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial

    Authors: Joan T. Merrill, Joel M. Guthridge, Miles Smith, Joshua June, Fotios Koumpouras, Wambui Machua, Anca Askanase, Arezou Khosroshahi, Saira Z. Sheikh, Gaurav Rathi, Bart Burington, Paul Foster, Mark Matijevic, Sujata Arora, Xiaodong Wang, Minggeng Gao, Stephen Wax, Judith A. James, Debra Zack - Arthritis & Rheumatology 2023 cited by 63

  19. Novel evidence‐based systemic lupus erythematosus responder index

    Authors: Richard Furie, Michelle Petri, Daniel J. Wallace, Ellen M. Ginzler, Joan T. Merrill, William Stohl, Winn Chatham, Vibeke Strand, Arthur Weinstein, Marc Chévrier, Z. John Zhong, William W. Freimuth - Arthritis Care & Research 2009 cited by 485

  20. Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus

    Authors: Joan T. Merrill, Victoria P. Werth, Richard Furie, Ronald van Vollenhoven, Thomas Dörner, Milan Petronijevic, Jorge Velasco, Maria Majdan, Fedra Irazoque-Palazuelos, Michael Weiswasser, Shimon Korish, Ying Ye, Allison Gaudy, Peter H. Schafer, Zhaohui Liu, Nataliya Agafonova, Nikolay Delev - New England Journal of Medicine 2022 cited by 107

  21. Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis

    Authors: Ellen M. Ginzler, Mary Anne Dooley, Cynthia Aranow, Mimi Kim, Jill P. Buyon, Joan T. Merrill, Michelle Petri, Gary S. Gilkeson, Daniel J. Wallace, Michael H. Weisman, Gerald B. Appel - New England Journal of Medicine 2005 cited by 1,127

  22. X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome

    Authors: Ke Liu, Biji T. Kurien, Sarah Zimmerman, Kenneth M. Kaufman, Diana H. Taft, Leah C. Kottyan, Sara Lázaro, Carrie A. Weaver, John A. Ice, Adam J. Adler, James Chodosh, Lida Radfar, Astrid Rasmussen, Donald U. Stone, David M. Lewis, Shibo Li, Kristi A. Koelsch, Ann Igoe, Mitali Talsania, Jay Kumar, Jacen S. Maier‐Moore, Valerie M. Harris, Rajaram Gopalakrishnan, Roland Jonsson, James Lessard, Xianglan Lu, Jacques‐Eric Gottenberg, Juan‐Manuel Anaya, Deborah S. Cunninghame‐Graham, Andrew Huang, Michael T. Brennan, Pamela Hughes, Gabor G. Illei, Corinne Miceli‐Richard, Edward Keystone, Vivian P. Bykerk, Gideon M. Hirschfield, Gang Xie, Wan‐Fai Ng, Gunnel Nordmark, Per Eriksson, Roald Omdal, Nelson L. Rhodus, Maureen Rischmueller, Michael D. Rohrer, Barbara Segal, Timothy J. Vyse, Marie Wahren‐Herlenius, Torsten Witte, Bernardo A. Pons‐Estel, Marta E. Alarcón‐Riquelme, Joel M. Guthridge, Judith A. James, Christopher J. Lessard, Jennifer A. Kelly, Susan D. Thompson, Patrick M. Gaffney, Courtney G. Montgomery, Jeffrey C. Edberg, Robert P. Kimberly, Graciela S. Alarcón, Carl Langefeld, Gary S. Gilkeson, Diane L. Kamen, Betty P. Tsao, W. Joseph McCune, Jane E. Salmon, Joan T. Merrill, Michael H. Weisman, Daniel J. Wallace, Tammy O. Utset, Erwin P. Böttinger, Christopher I. Amos, Katherine A. Siminovitch, Xavier Mariette, Kathy L. Sivils, John B. Harley, R. Hal Scofield - Arthritis & Rheumatology 2015 cited by 174

  23. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

    Authors: Joan T. Merrill, William Shanahan, Morton Scheinberg, Kenneth Kalunian, David Wofsy, Renée S. Martin - Annals of the Rheumatic Diseases 2018 cited by 155

  24. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

    Authors: Celline Cardoso Almeida-Brasil, John G. Hanly, Murray B. Urowitz, Ann E. Clarke, Guillermo Ruiz‐Irastorza, Caroline Gordon, Rosalind Ramsey‐Goldman, Michelle Petri, Ellen M. Ginzler, Daniel J. Wallace, Sang‐Cheol Bae, Juanita Romero‐Díaz, Mary Anne Dooley, Christine Peschken, David Isenberg, Anisur Rahman, Susan Manzi, Søren Jacobsen, Sam Lim, Ronald van Vollenhoven, Ola Nived, Andreas Jönsen, Diane L. Kamen, Cynthia Aranow, Jorge Sánchez‐Guerrero, Dafna D. Gladman, Paul R. Fortin, Graciela S. Alarcón, Joan T. Merrill, Kenneth Kalunian, Manuel Ramos‐Casals, Kristján Steinsson, Asad Zoma, Anca Askanase, Munther A. Khamashta, Ian N Bruce, Murat İnanç, Michał Abrahamowicz, Sasha Bernatsky - Annals of the Rheumatic Diseases 2021 cited by 98